Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy

Author(s): Silvio Roggo.

Journal Name: Current Topics in Medicinal Chemistry

Volume 2 , Issue 4 , 2002

Become EABM
Become Reviewer


The first proteolytic step in the processing of amyloid precursor protein (APP) to amyloid-beta (Aβ) in the brain is performed by β-site APP cleaving enzyme (BACE1). This enzyme is a membrane bound aspartic protease with high homology of the catalytic domain to renin and pepsin and of yet unknown physiologic function. It is a primary drug discovery target for Alzheimers disease therapy. The first potent inhibitors are based on the sequence of APP around the β-secretase cleavage site EVNL / DAEF, with the scissile Leu-Asp amide bond being replaced by a hydroxyethylene transition state analogue isostere. In addition, lipophilic sidechains have been incorporated and a crystal structure of such an octapeptidic inhibitor bound in the active site is already available. Recent progress in the field of BACE inhibition is reviewed.

Keywords: bace, aspartic protease, inhibition, app, amyliod, pepstatin, protease, indinavir, amprenavir, tipranavir, aliskiren

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [359 - 370]
Pages: 12
DOI: 10.2174/1568026024607490
Price: $65

Article Metrics

PDF: 7